Modern Healthspan: 17 Month Life Extension Headed to Human Trial!
Peer-Reviewed Research
Key Takeaways
- Watch for human trials of the DOS peptide intervention in elderly adults starting this year, focusing on immune function and vaccine response.
- Prioritize immune health as immunosenescence is a major contributor to late-life decline – this study suggests rejuvenating CD4 T-cells may have systemic benefits.
- Follow peer-reviewed updates – these mouse results (17-month lifespan extension) are promising but still preprint and need replication.
Notable Quotes
“The goal of the trial is to assess safety and see whether rejuvenating the immune system can improve vaccine responses in older adults particularly for influenza vaccines.”
Bottom Line
Track upcoming human trials of immune-rejuvenating therapies like DOS peptide, and maintain immune health through proven methods (vaccinations, exercise, nutrition) while awaiting further research.
Explore More
- Modern Healthspan’s Full Protocol — supplements, dosages, and daily routine
- Compare All Protocols — side-by-side protocols
Watch the Full Video
Medical Disclaimer
This article is for informational purposes only and does not constitute medical advice. The research summaries presented here are based on published studies and should not be used as a substitute for professional medical consultation. Always consult a qualified healthcare provider before making any changes to your health regimen.
Peer-reviewed health research, simplified. Early access findings, clinical trial alerts & regulatory news — delivered weekly.
No spam. Unsubscribe anytime. Powered by Beehiiv.
Related Research
From Our Research Network
Daily longevity researchZone2 Training
Exercise protocolsSleep Science
Sleep optimization
Part of the Evidence-Based Research Network